Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macimorelin for Diagnosis of Pediatric Growth Hormone Deficiency (DETECT)
NCT04786873Phase 3Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of macimorelin in growth hormone deficiency (GHD) (2 arms), sponsored by COSCIENS Biopharma Inc. Primary endpoint: Area under the Receiver Operator Characteristic curve. Started Nov 2021; status: completed.
02
Drugs
macimorelin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT04786873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786873.